Cost-Effective Combination Vaccines Offer Tremendous Growth Potential in the South...

Cost-Effective Combination Vaccines Offer Tremendous Growth Potential in the South African Paediatric Vaccines Markets

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c86823) has announced the
addition of "Strategic Analysis of the South African Paediatric
Vaccines Markets" to their offering.

This Frost & Sullivan research service titled Strategic Analysis
of the South African Paediatric Vaccines Markets provides an overview
of the South African healthcare industry in the context of paediatric
vaccines as divided between the private and public sector. The
research reveals the size of the market in both sectors as well as the
competitors operating within this market. In this research, Frost &
Sullivan's expert analysts thoroughly examine the South African public
and private paediatric vaccines sectors.

Vaccines, especially paediatric vaccines, are among the fastest
growing sectors in the pharmaceutical industry. Immunising
populations, especially children, against life-threatening diseases
offers a cost-effective manner of managing disease, particularly in
developing countries where the disease burden is usually more severe
than the developed world; vaccinations can save thousands of lives
daily. The emergence of combination vaccines has revolutionised the
South African paediatric vaccines industry. "The current trend in the
paediatric vaccine market is to combine existing vaccines - these
combination vaccines have caused a substantial increase in market
revenues," notes the analyst of this research. "Growth in the South
African private paediatric sector has risen significantly due to
combination vaccines available in the market." Combination vaccines
consist of up to nine antigens against various diseases incorporated
into one vaccine, leading to fewer injections per immunisation, higher
coverage rates and broader disease coverage.

Another emerging trend is that of therapeutic vaccines. Vaccine
manufacturers are ploughing significant capital and effort into
designing innovative vaccines that can treat/prevent HIV, malaria and
cancer, among other diseases. DNA technologies are being used to
develop these advanced, novel vaccines. Vaccines are essential to
finding cures for major diseases including HIV/AIDS and malaria. They
are also useful in preventing the occurrence of certain diseases
through providing enhanced immunity. For instance, vaccines limit
pneumococcal disease - a disease caused by a streptococcus strain that
builds up resistance against antibiotics and leads to the death of
almost 800,000 children annually across the globe.

Private Paediatric Vaccines Sector Represents High-margin,
Low-volume Model, while Public Sector Represents High-volumes,
Low-margin Model

In South Africa, the paediatric vaccine market within the private
sector has increased significantly over the last three to four years.
This has been due to the launch of new combination and novel vaccines
not covered by the government's extended immunisation programme (EPI).
In South Africa, the biggest challenge is to serve the public market
through the government's EPI. Although revenues are high, volumes are
low in the private sector; in the public sector, this model is
reversed. Government's price-sensitive contracts, slow adoption of new
technology and question marks around the disease burden of these new
vaccines make it challenging for manufacturers to supply paediatric
vaccines to the public sector.

The government revises the EPI programme annually, but due to a
tight budget allocated to paediatric vaccines, the process of adopting
new vaccines into the programme relies on the cost of the vaccines and
the severity of the disease burden that can be prevented by these
vaccines. Vaccine manufacturers can overcome this challenge by
reducing the manufacturing costs. "Optimising processes in research
and development to be more cost effective will allow manufacturers to
reduce the price of paediatric vaccines and boost their chances of
entering the EPI programme," advises the analyst. "Apart from cost, it
is important to justify the vaccine; paediatric vaccines are only
accepted by government if the specific disease burden covered by the
vaccine is severe enough - combination and 'novel' vaccines can play a
huge role here."

Expert Frost & Sullivan analysts thoroughly examine the following
market sectors in this research:

- Public paediatric vaccines sector

- Private paediatric vaccines sector

Discussions

An Overview of the South African Paediatric Vaccines Markets:

- Executive Summary

- Research Scope and Methodology

- South African Paediatric Vaccines Market

- Decision Support Databases

For more information visit
http://www.researchandmarkets.com/reports/c86823

Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008